HIM
TCRR

Hillhouse Investment Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Hillhouse Investment Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$4.62M Hold
322,903
– – 0.15% 30
2019
Q1 		$5.63M Buy
+322,903
New +$5.73M 0.23% 28

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillhouse Investment Management's TCRR Position: Q2 2019 in Review

Hillhouse Investment Management held its TCR2 Therapeutics Inc. Common Stock (TCRR) position steady in Q2 2019 at 322,903 shares worth $4.62M. The position accounts for 0.15% of the portfolio, ranked #30.

Hillhouse Investment Management first reported a position in TCRR in Q1 2019 and has held it in 2 quarters since. The position peaked at $5.63M in Q1 2019. 33 funds tracked by Wall St. Rank hold TCRR as of Q2 2019.

  • Hillhouse Investment Management held 322,903 shares of TCR2 Therapeutics Inc. Common Stock worth $4.62M as of Q2 2019.
  • Hillhouse Investment Management left its TCR2 Therapeutics Inc. Common Stock share count unchanged in Q2 2019.
  • TCR2 Therapeutics Inc. Common Stock made up 0.15% of Hillhouse Investment Management's portfolio in Q2 2019, its #30 holding.
  • Hillhouse Investment Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and has held it in 2 quarters since.
  • Hillhouse Investment Management's TCR2 Therapeutics Inc. Common Stock position peaked at $5.63M in Q1 2019.
  • 33 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2019.

Based on Hillhouse Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.